Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03468855 | A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo | PHASE2 | COMPLETED | 34 | — | — | Mar 19, 2018 | Oct 16, 2019 | Nov 30, 2020 | 5 | United States |
Mean change from baseline in facial depigmentation in quantified Area of Interest (AOI) using Canfield-2-D photographic image analysis from baseline (Visit 2) compared to Week 24. Facial depigmentation is measured on a scale of 0 to 100, with a score of 0 meaning no depigmentation and a score of 100 meaning total depigmentation. Lower scores represent better outcomes.
| Arm | Type | Description |
|---|---|---|
| ATI-50002 Topical Solution | EXPERIMENTAL | ATI-50002 topical solution, high dose active, twice-daily, 24 weeks |
| Name | Type | Description |
|---|---|---|
| ATI-50002 topical solution | DRUG | Topical Solution administered twice daily |
Inclusion Criteria: 1. Subject has a clinical diagnosis of new onset or actively progressing non-segmental facial vitiligo or worsening of existing facial lesions within the past 6 months. 2. Subject has non-segmental facial vitiligo effecting at least 0.25% total body surface area (TBSA) (excludin...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 5 | PHASE3 | Povorcitinib, Ruxolitinib, Vehicle |
| Pfizer Inc. | PFE | 2 | PHASE3 | Ritlecitinib |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Upadacitinib |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | GIA632 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE2 | Roflumilast 0.3% foam |
| Forte Biosciences Inc. | FBRX | 1 | PHASE1 | FB102 |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 1 | PHASE1 | TEV-53408 |